Atazanavir
- 1 January 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 63 (16), 1679-1693
- https://doi.org/10.2165/00003495-200363160-00003
Abstract
▴ Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. ▴ The resistance profile of atazanavir is distinct, with an I50L protease substitution appearing to be the signature mutation. ▴ Atazanavir was not associated with increases in total cholesterol, low density lipoprotein-cholesterol or triglyceride levels after 108 weeks. ▴ Atazanavir has a pharmacokinetic profile that allows for once-daily oral administration. It is a moderate inhibitor of hepatic cytochrome P450 enzymes and interacts with several drugs. ▴ In combination with stavudine plus didanosine, atazanavir 200, 400 or 500mg once daily produced a rapid and sustained reduction from baseline in viral load of 2.57, 2.42 and 2.53 log10 copies/mL, respectively, in treatment-naive patients after 48 weeks, compared with a decrease of 2.33 log10 copies/mL with nelfinavir 750mg three times daily. ▴ Nausea was the most clinically relevant adverse event reported in patients receiving atazanavir-based regimens.Keywords
This publication has 10 references indexed in Scilit:
- Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trialAIDS, 2003
- Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2003
- Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Atazanavir: a novel HIV-1 protease inhibitorExpert Opinion on Investigational Drugs, 2002
- Antiretroviral Treatment for Adult HIV Infection in 2002JAMA, 2002
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapyHIV Medicine, 2001
- Hollow‐Fiber Unit Evaluation of a New Human Immunodeficiency Virus Type 1 Protease Inhibitor, BMS‐232632, for Determination of the Linked Pharmacodynamic VariableThe Journal of Infectious Diseases, 2001
- BMS-232632 (Novartis/Bristol-Myers Squibb).2001
- In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632Antimicrobial Agents and Chemotherapy, 2000
- BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral AgentsAntimicrobial Agents and Chemotherapy, 2000